Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma
1 clinical trials · Condition
◉ Watch Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NCT03703050) | Gustave Roussy, Cancer Campus, Grand Paris | 2019-01-02 |
Track Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.